Synonyms: 311C90 | Zomig®
zolmitriptan is an approved drug (FDA (1997))
Compound class:
Synthetic organic
Comment: Zolmitriptan is triptan type serotonin receptor agonist that is used as an anti-migraine drug. It is selective for the 1B and 1D 5-HT receptor subtypes. Zolmitriptan is the only triptan known to be converted to an active N-desmethyl metabolite which has higher affinity for the 5-HT1D and 5-HT1B receptors than the parent molecule
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: zolmitriptan |
|
No information available. |
Mechanism Of Action and Pharmacodynamic Effects |
The high affinity binding of zolmitriptan to 5-HT1B and 5-HT1D receptors causes constriction of the cranial blood vessels in which these receptors are expressed, which has the effect of inhibiting the release of migraine-causing pro-inflammatory neuropeptides such as calcitonin gene-related peptide (CGRP) and substance P. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com |